We aimed to compare the protective eect of single doses of 4?5 and 9 mg of formoterol fumarate (F), 0?5 mg terbutaline sulphate (T) and placebo (P), all via Turbuhaler 1 , against exercise-induced bronchoconstriction (EIB) in children.
Introduction
Strenuous physical activity is often associated with symptoms of airway obstruction in children suering from asthma. In some children exercise is the only trigger, whereas in others it is one of several stimuli which trigger symptoms (1) . In clinical investigations, exercise tests resulted in bronchoconstriction in more than 70% of asthmatic children (2±4). Exercise-induced bronchoconstriction (EIB) is thought to be elicited by airway cooling (5) and respiratory water loss (6) , which causes a change in osmolality of the pericilliary¯uid lining the respiratory tract (7) . Cold air in combination with exercise, which represents a commonly encountered stimulus during the daily life of many asthmatic individuals, especially in winter, markedly worsened EIB in children with asthma (8).
Short-acting inhaled b 2 -agonists, when taken before exercise, have been shown to reduce/prevent EIB in most patients (9, 10) . According to current international guidelines for treatment of asthma (11) , they are the drugs of choice for the prevention and treatment of EIB. However, the bene®t of these drugs is limited by their short duration of protection (1) . When treating children with asthma, one has to take into account their special needs and lifestyle, for example participation in organized school sporting and other spontaneous physical activity during the day. Uncontrolled symptoms limit participation in such activities and may impair self-esteem (12) and quality of life (13, 14) . Oxis 1 Turbuhaler 1 combines the pharmacodynamic advantage of formoterol, such as rapid onset and long duration of action (15, 16) with the user convenience and higher lung deposition of Turbuhaler 1 (17) . In a 3-month ecacy and safety study in children, formoterol was shown to be signi®cantly superior to placebo in improving morning peak expiratory¯ow (PEF) (18) . When compared with terbutaline 0?5 mg b.i.d. in two 3-month studies in adults, formoterol Turbuhaler at both 4?5 and 9 mg b.i.d. was statistically signi®cantly better in the control of asthma (19, 20) . Concerning the protection against EIB in children, a single dose of formoterol (metered dose) 12 mg via pressurized metered dose inhaler gave a signi®cantly prolonged protection compared with salbutamol 200 mg; the protection persisted for 12 h (21). Similar outcomes were seen in adults in a study comparing 9 mg formoterol Turbuhaler and 0?5 mg terbutaline Turbuhaler (22) .
This study compared the bronchoprotection of single doses of formoterol Turbuhaler at delivered doses of 4?5 mg and 9 mg with that of 0?5 mg terbutaline Turbuhaler and of placebo, against repeated exercise challenge combined with cold air in children during a period of 12 h.
Patients and methods

PATIENTS
Patients with asthma, as de®ned by the ATS (23), strati®ed into two age groups; 6±12 and 13±17 years were enrolled.
To be included, they should have a baseline FEV 1 of !80% of predicted normal value (24) and had to show a fall of !20% in FEV 1 following a standardized exercise challenge test (ECT).
DESIGN
This was a randomized, double-blind, placebo-controlled, cross-over study performed at two centres: one in Norway and one in Germany. The study consisted of ®ve visits comprising one screening and four 12-h study days (visits 2±5), separated by washout periods of at least 72 h.
On study days, the patients inhaled 4?5 or 9mg formoterol fumarate dehydrate (hereafter formoterol), 0?5 mg terbutaline sulphate (hereafter terbutaline) or placebo, all via Turbuhaler, in a randomized order.
Spirometry
Schedule of spirometry test during study days is presented in Fig. 1 . Two FEV 1 determinations (separated by 15 min) were performed before study drug administration. The mean of the two was used as baseline FEV 1 and had to be !80% of predicted normal value at visits 1±5. The variation in baseline FEV 1 at visits 2±5 had to be within 20% of the mean baseline FEV 1 value at visit 1.
FEV 1 was measured before, immediately after, and 5, 10 and 20 min after ECT. If FEV 1 was lower after 20 min than after 10 min, measurements continued every 10 min until the maximum fall was observed.
Exercise challenge test (ECT)
ECTs were performed 15 min and 4, 8 and 12 h after drug administration. The ECT at visit 1 was carried out to determine if the patient responded to exercise with a decline in FEV 1 of at least 20% of his/her baseline value. The patients performed a continuous running test on a treadmill (25) with a workload adjusted to produce a maximum pulse (approximately 180 beats min 71 ). During exercise the patients inhaled cold dry air (7108C) generated by the Turboaire 1 challenger through compressed medical air with a pressure of 6 bar, through a mouthpiece. The duration of the test varied between 4 and 8 min, depending on the time required to reach a maximum pulse. The individual workload established at enrolment for each patient was maintained throughout the study. Pulse was measured before, during and immediately after the running period.
Before each ECT, the investigator had to judge whether it was possible and safe for the patient to perform the ECT. If not, the patient has to rest until the next scheduled ECT. To exclude a possible late phase reaction, PEF was measured at the clinic and then at home at 4, 8 and 12 h after the ECT at visit 1.
FIG. 1. Spirometry tests during study days.
Patients discontinued any concomitant use of bronchodilators 6±72 h prior to visits, depending on the duration of drug action. Anti-histamines and disodium cromoglycate were discontinued 48 and 24 h, respectively, prior to visits. Inhaled and nasal glucocorticosteroids (GCSs) were allowed, provided that they were used at constant doses 30 days prior to visit 1 and throughout the study.
Pharmacodynamic parameters
AUC 0±20 : The area under the time±eect curve in the interval 0±20 min was computed using the trapezoidal rule. AUC 0±12 h : The area under the time±eect curve in the interval 0±12 h. E base :
The mean of the two FEV 1 measurements at the beginning of each study day (before study drug at visits 2±5). E pre :
FEV 1 just before each ECT. E min :
The minimum post-exercise value measured. E av :
The average eect based on E pre within the study day, i.e. AUC 0±12 h /12. Index EIB : The bronchial response to exercise was expressed as maximum fall in FEV 1 from the preexercise value (the % fall index): 
Statistics
In a previous study in children, the within patient coecient of variation in the lowest post-exercise vs. pre-exercise FEV 1 ratio was 13%. With similar variation in this study, a sample size of 24 evaluable patients would give a probability of 80% to detect an eect of 11%. This assumed a two-sided test on a 5% signi®cance level. Index EIB was compared between treatments with an additive analysis of variance (ANOVA) model with factors patient, visit and treatment. 95% con®dence intervals were constructed for the pair-wise treatment comparisons. The values from each exercise test within a study day were treated in separate analyses. The duration of the protective eect was evaluated by comparing the active treatments with placebo at 15 min and then for as long as the dierence was statistically signi®cant.
Possible dierences in treatment eects between the two age groups (6±12 and 13±17 years) were investigated using a separate ANOVA model.
Ethics
Independent Ethics Committees in Norway and Germany approved the study. Signed informed consent was obtained from the parent and from the patient if he/she was older than 12 years or oral consent if the child was younger than 12 years, prior to enrolment in the study.
Results
Twenty-seven patients (15 males and 12 females) were randomized into the study. Their mean age was 12?6 years (range 8±17 years), mean weight 47 kg (25±71 kg) and mean height 154 cm (135±180 cm). All but two were Caucasians. Thirteen children belonged to the younger age group (6±12 years) and 14 to the older age group (13±17 years). The mean baseline FEV 1 (E base ) at visit 1 was 2?56 l (1?66±4?15 l) corresponding to 90% of predicted normal value (74± 106%). The mean percentage fall in FEV 1 after exercise at enrolment (Index EIB ) was 32% (19?7±49?5%). The distribution of some patient characteristics at entry is shown in Fig. 2 .
Seventeen patients were on regular treatment with inhaled GCSs (120±750 mg) and four patients were using a long-acting b 2 -agonist (salmeterol) on a regular basis. Eight patients used anti-histamines; one patient used inhaled disodium cromoglycate, one patient used nasal disodium cromoglycate and two patients used nasal GCSs.
FEV 1 BEFORE ECT
Mean baseline FEV 1 measured before drug administration (E base ) was about the same for all treatments; 2?50 l (placebo), 2?56 l (formoterol 4?5 mg), 2?55 l (formoterol 9 mg) and 2?52 l (terbutaline 0?5 mg). Both doses of formoterol as well as terbutaline gave statistically signi®-cantly higher FEV 1 values than placebo, 15 min after administration (Table 1) . No statistically signi®cant dierence was seen between the 4?5 and 9 mg dose of formoterol (Fig. 3) .
Concerning a 12 h average of pre-exercise FEV 1 (E av ), both formoterol doses gave signi®cantly higher bronchodilating eects than both placebo and terbutaline.
PROTECTION AGAINST EIB
Both formoterol doses gave a signi®cantly higher degree of protection against EIB than placebo, between 15 min and 12 h after study drug administration. Compared with terbutaline, both formoterol doses gave a signi®cantly better protection at 4, 8 and 12 h after drug administration. Fifteen minutes after drug administration, terbutaline gave a signi®cantly better protection than placebo. The eect declined, reaching the same level as placebo at the exercise test performed 4 h after administration (Fig. 4) . The mean fall in FEV 1 after placebo during the randomized study days was 18?4% at the 15-min test, which was less than the mean fall measured at the screening visit (32?0%). The results of the statistical analyses are given in Table 2 . No major dierences were seen between the age groups concerning the treatment eects (Fig. 5) . Statistical tests comparing treatments were not made due to the limited number of patients in each subgroup.
SAFETY
There were no adverse events of clinical relevance or considered causally related to treatment.
Discussion
The current guidelines (11) exacerbation associated with exercise and other stimuli, which trigger bronchoconstriction. The present results demonstrate that long-acting formoterol Turbuhaler is a superior alternative to short-acting terbutaline in protection against bronchoconstriction induced by a repeated exercise during a period of 12 h. The technique of repeated exercise test after a single dose re¯ects the daily life situation for many children, which includes scheduled physical activities such as school sporting activities and other unplanned activities, during the day. A practical implication of the present results is that the children need only to take one single dose in the morning and may then feel con®dent to take part in physical activities without needing to carry any rescue inhaler or to think about timing an extra inhalation before exercise. The children will not feel dierent from other children, which should have positive impact on their self con®dence and quality of life (12±14). The fall in FEV 1 during the randomized placebo day was smaller than the mean fall seen at the screening day (18% compared with 32%), indicating a placebo eect. A similar eect on EIB has been reported before (26, 27) . Both formoterol and terbutaline had a limited bronchodilating eect, 7 and 6% after 4?5 and 9 mg formoterol respectively and 5% after terbutaline. This is what would be expected in patients with relatively high baseline FEV 1 (74±106% of predicted normal value). A reversibility test was not performed in these patients; the main inclusion criterion was a fall in FEV 1 after exercise. A high baseline FEV 1 was chosen as a safety measure to avoid very low post-exercise FEV 1 and to eliminate the contribution of bronchodilating eect to the protection against EIB.
In contrast to the long acting b 2 -agonists, the shortacting drugs have demonstrated shorter duration of bronchoprotective eect against exercise than that of the bronchodilatory eect (25) . This was also applicable in the present study. Both formoterol and terbutaline gave statistically signi®cant protection relative to placebo against bronchoconstriction induced by exercise performed at 15 min after drug administration. The protection of formoterol lasted for 12 h, while that of terbutaline was the same as after placebo during exercise performed 4 h after administration. Prolonged bronchoprotection of formoterol during exercise was also shown in adults on regular treatment with formoterol Turbuhaler 9 mg b.i.d. A statistically signi®cant protection against EIB for up to 12 h was shown after a mean treatment period of 16 days (range 8±44 days). Although the protection was somewhat lower at the 12-h ECT compared to what was seen earlier in the day, formoterol had about three times longer duration of eect than the short-acting bronchodilators normally used for the prevention of EIB (22) . A prolonged protective eect of long-acting b 2 -agonists against bronchoconstriction induced by other stimuli has been reported in previous investigations (28±30).
Despite the fact that a majority of the patients were on regular use of inhaled GCSs, they all showed a fall in FEV 1 after exercise. In these patients, a single dose of formoterol 4?5 or 9 mg was seen to give the protection they needed against EIB.
In conclusion formoterol was shown to be a better alternative to terbutaline against bronchoconstriction induced by repeated exercise challenge for up to 12 h in children.
